Cancer Research Technology
Log in Register
Menu

STAT2-Defective Mutant Daudi (RST2) cell line

Invented by Dr. Lawrence Pfeffer at The University of Tennessee Health Science Center

Info

Catalogue Number 156502
Parental Line Human Daudi Burkitt Lymphoma cell line
Host Human
Tissue Blood
Disease Keywords Burkitt lymphoma
Model Transgenic
Relevance This cell line can be used to study drug resistance developed after treatment with interferon. Interferon therapy has been proved as a successful treatment for various types of cancer, however it develops resistance in patients. This cell line was not affected by the antiviral, antiproliferative, and gene-inducing actions of IFN.
Production Details Isolated from IFN-sensitive Daudi cell line by growth in the continuous presence of IFN
Research Area Cancer
Recommended Growing Conditions RPMI1640 and 10% defined calf serum; Subculture 1:4 twice a week, maintain 1 and 10X10^5 cells/mL

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Schmeisser et al. 2013. Autophagy. 9(5):683-96. PMID: 23419269.

Du et al. 2009. J Biol Chem. 284(41):27808-15. PMID: 19687011.


Add a reference

References: 2 entries

Schmeisser et al. 2013. Autophagy. 9(5):683-96. PMID: 23419269.

Du et al. 2009. J Biol Chem. 284(41):27808-15. PMID: 19687011.


Add a reference

Inventor Information